利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.019 秒)

    Purine derivatives
    2.
    发明授权
    Purine derivatives 失效
    嘌呤衍生物

    公开(公告)号：US4965270A

    公开(公告)日：1990-10-23

    申请号：US433011

    申请日：1989-11-07

    申请人： Michael R. Harnden ,  Paul G. Wyatt ,  Stuart Bailey

    发明人： Michael R. Harnden ,  Paul G. Wyatt ,  Stuart Bailey

    IPC分类号： C07D473/16 ,  C07D473/18 ,  C07D473/32

    CPC分类号： C07D473/18 ,  C07D473/16 ,  C07D473/32

    摘要： Compounds of formula (I), and pharmaceutically acceptable salts thereof: ##STR1## wherein R.sub.1 is hydrogen or CH.sub.2 OH;R.sub.2 is hydrogen or, when R.sub.1 is hydrogen, hydroxy or CH.sub.2 OH;R.sub.3 is CH.sub.2 OH or, when R.sub.1 and R.sub.2 are both hydrogen, CH(OH)CH.sub.2 OH;R.sub.4 is hydrogen, hydroxy, amino or OR.sub.5 whereinR.sub.5 is C.sub.1-6 alkyl, phenyl or phenyl C.sub.1-2 alkyl either of which phenyl moieties may be substituted by one or two halo, C.sub.1-4 alkyl or C.sub.1-4 alkoxy groups;and in which any OH groups in R.sub.1, R.sub.2 and R.sub.3 may be in the form of O-acyl, phosphate, cyclic acetal or cyclic carbonate derivatives thereof; having antiviral activity.

    摘要翻译： 式（I）化合物及其药学上可接受的盐：其中R 1是氢或CH 2 OH; R2是氢或当R1是氢时羟基或CH2OH; R 3是CH 2 OH，或当R 1和R 2均为氢时，CH（OH）CH 2 OH; R4是氢，羟基，氨基或OR5，其中R5是C1-6烷基，苯基或苯基C1-2烷基，其中苯基部分可以被一个或两个卤素，C1-4烷基或C1-4烷氧基取代; 其中R 1，R 2和R 3中的任何OH基可以是O-酰基，磷酸酯，环状缩醛或环状碳酸酯衍生物的形式; 具有抗病毒活性。

    Purine derivatives
    4.
    发明授权
    Purine derivatives 失效
    嘌呤衍生物

    公开(公告)号：US5250688A

    公开(公告)日：1993-10-05

    申请号：US825440

    申请日：1992-01-22

    申请人： Michael R. Harnden ,  Richard L. Jarvest

    发明人： Michael R. Harnden ,  Richard L. Jarvest

    IPC分类号： C07C69/007 ,  C07D473/00 ,  C07F9/6561 ,  C07D473/34 ,  A61K31/52

    CPC分类号： C07D473/00 ,  C07C69/007 ,  C07F9/65616

    摘要： A compound of formula (I) ##STR1## or a salt thereof, wherein R.sub.1 and R.sub.2 are each independently hydrogen, acyl or phosphate, provided that when one of R.sub.1 or R.sub.2 is phosphate, the other is hydrogen; or R.sub.1 and R.sub.2 are joined together to form a cyclic acetal group, a cyclic carbonate group or a cyclic phosphate group.Processes for preparing these compounds and their use in therapy is also described.

    摘要翻译： 式（I）化合物或其盐，其中R 1和R 2各自独立地为氢，酰基或磷酸酯，条件是当R 1或R 2中的一个为磷酸酯时，另一个为氢; 或R 1和R 2连接在一起形成环状缩醛基，环状碳酸酯基或环状磷酸酯基。 还描述了制备这些化合物及其在治疗中的用途的方法。

    Purine derivatives having antiviral activity
    8.
    发明授权
    Purine derivatives having antiviral activity 失效
    具有抗病毒活性的嘌呤衍生物

    公开(公告)号：US5055458A

    公开(公告)日：1991-10-08

    申请号：US387068

    申请日：1989-07-28

    申请人： Stuart Bailey ,  Michael R. Harnden

    发明人： Stuart Bailey ,  Michael R. Harnden

    IPC分类号： A61K31/675 ,  A61P31/12 ,  A61P35/00 ,  C07F9/40 ,  C07F9/6506 ,  C07F9/6512 ,  C07F9/6561

    CPC分类号： C07F9/65616 ,  C07F9/4006 ,  C07F9/65067 ,  C07F9/65127

    摘要： Compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein R.sub.1 is hydroxy, amino, chloro or OR.sub.7 whereinR.sub.7 is C.sub.1-6 alkyl, phenyl or phenyl C.sub.1-2 alkyl either of which phenyl moieties may be substituted by one or two substituents selected from halo, C.sub.1-4 alkyl or C.sub.1-4 alkoxy;R.sub.2 amino or, when R.sub.1 is hydroxy or amino, R.sub.2 may also be hydrogen;X is --CH.sub.2 CH.sub.2 -- or a moiety of structure (a), (b) or (c): ##STR2## wherein n is 1 or 2;m is 0, 1 or 2; andR.sub.3 is hydrogen or acyl;R.sub.4 is a group of formula: ##STR3## wherein R.sub.5 and R.sub.6 are independently selected from hydrogen, C.sub.1-6 alkyl and optionally substituted phenyl; having antiviral activity, processes for their preparation and their use as pharmaceuticals.

    Antiviral purine compounds
    10.
    发明授权
    Antiviral purine compounds 失效
    抗病毒嘌呤化合物

    公开(公告)号：US5247085A

    公开(公告)日：1993-09-21

    申请号：US892601

    申请日：1992-05-29

    申请人： Michael R. Harnden ,  David M. Duckworth

    发明人： Michael R. Harnden ,  David M. Duckworth

    IPC分类号： C07F9/40 ,  C07F9/6506 ,  C07F9/6512 ,  C07F9/6561 ,  C07F9/6571

    CPC分类号： C07F9/657181 ,  C07F9/4006 ,  C07F9/65061 ,  C07F9/65127 ,  C07F9/65616

    摘要： Compounds of formula (I), and pharmaceutically acceptable salts thereof ##STR1## wherein R.sub.1 is hydroxy, amino, chloro or OR.sub.7 whereinR.sub.7 is C.sub.1-6 alkyl, phenyl or phenyl C.sub.1-2 alkyl either of which phenyl moieties may be substituted by one or two substituents selected from halo, C.sub.1-4 alkyl or C.sub.1-4 alkoxy;R.sub.2 is amino or, when R.sub.1 is hydroxy or amino, R.sub.2 may also be hydrogen;R.sub.3 is hydrogen, hydroxymethyl or acyloxymethyl;R.sub.4 is a group of formula: ##STR2## R.sub.5 and R.sub.6 are independently selected from hydrogen, C.sub.1-6 alkyl and optionally substituted phenyl; orR.sub.3 and R.sub.4 together are: ##STR3## wherein R.sub.6 is as defined above;having antiviral activity, to processes for their preparation and their use as pharmaceuticals.

    摘要翻译： 式（I）化合物及其药学上可接受的盐其中R 1是羟基，氨基，氯或OR 7，其中R 7是C 1-6烷基，苯基或苯基C 1-2烷基，其中苯基部分可以是 被一个或两个选自卤素，C 1-4烷基或C 1-4烷氧基的取代基取代; R2是氨基，或当R1是羟基或氨基时，R2也可以是氢; R3是氢，羟甲基或酰氧基甲基; R 4是下式的基团：R 5和R 6独立地选自氢，C 1-6烷基和任选取代的苯基; 或者R 3和R 4一起是：其中R 6如上定义; 具有抗病毒活性，其制备方法及其作为药物的用途。